thalidomide has been researched along with Acute Confusional Senile Dementia in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The potential benefits of a novel TNF-α-lowering agent, 3,6'-dithiothalidomide, were investigated in cellular and rodent models of neuroinflammation with a specific focus on AD." | 7.78 | Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. ( Barlati, S; Bosetti, F; Caracciolo, L; Ferguson, RA; Fishman, K; Frankola, KA; Greig, NH; Holloway, HW; Lahiri, DK; Li, Y; Luo, W; Ray, B; Rosi, S; Russo, I; Tweedie, D; Van Praag, H, 2012) |
| "The potential benefits of a novel TNF-α-lowering agent, 3,6'-dithiothalidomide, were investigated in cellular and rodent models of neuroinflammation with a specific focus on AD." | 3.78 | Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. ( Barlati, S; Bosetti, F; Caracciolo, L; Ferguson, RA; Fishman, K; Frankola, KA; Greig, NH; Holloway, HW; Lahiri, DK; Li, Y; Luo, W; Ray, B; Rosi, S; Russo, I; Tweedie, D; Van Praag, H, 2012) |
| "Among the 25 participants, 14 (56%) terminated early due to adverse events, dramatically decreasing the power of the study." | 2.84 | Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial. ( Ahmadi, M; Belden, C; Decourt, B; Drumm-Gurnee, D; Gonzales, A; Jacobson, S; Macias, M; Powell, J; Sabbagh, MN; Shill, H; Sirrel, S; Walker, A; Wilson, J, 2017) |
| "Thalidomide is a tumor necrosis factor alpha (TNFα) inhibitor which has been found to have abilities against tumor growth, angiogenesis and inflammation." | 1.39 | Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. ( Cheng, X; He, P; Li, R; Shen, Y; Staufenbiel, M, 2013) |
| "Thalidomide treatment attenuated significantly STZ induced cognitive impairment and histopathological changes." | 1.39 | Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. ( Alan, S; Elçioğlu, H; Kabasakal, L; Karan, M; Salva, E; Tufan, F, 2013) |
| "Current Alzheimer's disease interventions are symptomatic treatments with limited efficacy that do not address etiology." | 1.38 | Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. ( Eslami, P; Gabbita, SP; Greig, NH; Harris-White, ME; Johnson, MF; Kobritz, NK; Sharma, SP; Srivastava, MK; Tweedie, D; Zemlan, FP, 2012) |
| "Thalidomide treatment in vivo was also associated with a significant reduction in hippocampal neuronal loss." | 1.35 | Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. ( McLarnon, JG; Ryu, JK, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McLarnon, JG | 2 |
| He, P | 1 |
| Cheng, X | 1 |
| Staufenbiel, M | 1 |
| Li, R | 1 |
| Shen, Y | 1 |
| Decourt, B | 1 |
| Drumm-Gurnee, D | 1 |
| Wilson, J | 1 |
| Jacobson, S | 1 |
| Belden, C | 1 |
| Sirrel, S | 1 |
| Ahmadi, M | 1 |
| Shill, H | 1 |
| Powell, J | 1 |
| Walker, A | 1 |
| Gonzales, A | 1 |
| Macias, M | 1 |
| Sabbagh, MN | 1 |
| Gabbita, SP | 1 |
| Srivastava, MK | 1 |
| Eslami, P | 1 |
| Johnson, MF | 1 |
| Kobritz, NK | 1 |
| Tweedie, D | 2 |
| Greig, NH | 2 |
| Zemlan, FP | 1 |
| Sharma, SP | 1 |
| Harris-White, ME | 1 |
| Ferguson, RA | 1 |
| Fishman, K | 1 |
| Frankola, KA | 1 |
| Van Praag, H | 1 |
| Holloway, HW | 1 |
| Luo, W | 1 |
| Li, Y | 1 |
| Caracciolo, L | 1 |
| Russo, I | 1 |
| Barlati, S | 1 |
| Ray, B | 1 |
| Lahiri, DK | 1 |
| Bosetti, F | 1 |
| Rosi, S | 1 |
| Elçioğlu, H | 1 |
| Kabasakal, L | 1 |
| Alan, S | 1 |
| Salva, E | 1 |
| Tufan, F | 1 |
| Karan, M | 1 |
| Ryu, JK | 1 |
| Alkam, T | 1 |
| Nitta, A | 1 |
| Mizoguchi, H | 1 |
| Saito, K | 1 |
| Seshima, M | 1 |
| Itoh, A | 1 |
| Yamada, K | 1 |
| Nabeshima, T | 1 |
1 review available for thalidomide and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Dapsone; Drug Therapy, Combination; Humans; Ibuprofen; Inflammation; Min | 2019 |
1 trial available for thalidomide and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Double-Blind Method; Educational Status; Fema | 2017 |
6 other studies available for thalidomide and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; As | 2013 |
Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Cognition Disorders; Disease Models, Animal; Humans; Ma | 2012 |
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biomarkers; Disease Models, Animal; Inflammation; Male; Maze Learning; M | 2012 |
Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Brain; Disease Models, Animal; Injections, Intravent | 2013 |
Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Angiogenesis Inhibitors; Animals; Br | 2008 |
Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Hippocampus; Immunosuppressive Agents; Injections | 2008 |